



AMDL Contact:
Kristine Szarkowitz
Director-Investor Relations
kszarkowitz@radient-pharma.com
(Tel :) 206.310.5323

FOR IMMEDIATE RELEASE

RADIANT PHARMACEUTICALS PUBLISHES WHITE PAPER HIGHLIGHTING ECONOMIC & HEALTHCARE BENEFITS OF GOVERNMENT SUPPORTED CANCER SCREENING

(TUSTIN, CA) March 23, 2010/PRNewswire – US-based pharmaceutical company Radiant Pharmaceuticals Corporation's (RPC) (NYSE - AMEX: [RPC](#) - [News](#)) wholly-owned subsidiary AMDL Diagnostics, Inc. (ADI), announced today it is making available its whitepaper, "Radiant Pharmaceuticals Corporation National and Regional Cancer Screening Programs."

The paper introduces RPC's newly launched General Cancer Screening Program designed to accelerate government support for general cancer screening in various international countries that include Australia, Brazil, Canada, China, Columbia, France, Germany, India, Spain, Saudi Arabia, the United Kingdom and the United States. The paper also outlines the tremendous economic and healthcare benefits of routine cancer screening, including the potential to detect cancer(s) in their earliest stages where the disease is the most preventable and/or treatable; and the merits of RPC's Onko-Sure™ in vitro diagnostic cancer test that enables physicians and their patients to effectively monitor and/or detect solid tumor cancers in early stages.

Specific topics covered in the whitepaper include:

- Overview of RPC's General Cancer Screening Program
- National & Regional Healthcare Screening Initiatives
- Radiant Pharmaceuticals Onko-Sure™ IVD Cancer Test Kit
- Improving Cancer Survivability & Healthcare Outcomes
- How to Implement a General Cancer Screening Program
- International Economics of Cancer Testing & Treatment

To obtain a copy of the "Radiant Pharmaceuticals Corporation National and Regional Cancer Screening Programs" whitepaper please visit www.radiant-pharma.com.

RPC's Onko-Sure IVD Cancer Test

Onko-Sure is a simple, non-invasive, patent-pending and regulatory-approved cancer test. For tested patients, Onko-Sure™ measures the accumulation of specific breakdown products in the blood called Fibrin and Fibrinogen Degradation Products (FDP) – products that are often underestimated by other tests. For additional information on Radiant Pharmaceuticals, ADI and its portfolio of products visit the Company's corporate website at www.Radiant-Pharma.com.

For Investor Relations information contact Kristine Szarkowitz at kszarkowitz@Radient-Pharma.com or 1.206.310.5323.

About Radient Pharmaceuticals:

Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is an integrated pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, and premium skin care products. For additional information visit www.radient-pharma.com.

Forward Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

###